key: cord-0293171-x1ikq8xu
authors: Akashi, Y.; Horie, M.; Kiyotaki, J.; Takeuchi, Y.; Togashi, K.; Adachi, Y.; Ueda, A.; Notake, S.; Nakamura, K.; Terada, N.; Kurihara, Y.; Kiyasu, Y.; Suzuki, H.
title: Clinical Performance of the cobas Liat SARS-CoV-2 & Influenza AB for the Detection of SARS-CoV-2 in Nasal Samples
date: 2022-01-10
journal: nan
DOI: 10.1101/2022.01.07.22268874
sha: e7e0a70d73a0301231738567ed3efda56426a643
doc_id: 293171
cord_uid: x1ikq8xu

Background and Objective: Point-of-care type molecular diagnostic tests have been used for detecting SARS-CoV-2, although their clinical utility with nasal samples has yet to be established. This study evaluated the clinical performance of the cobas Liat SARS-CoV-2 & Influenza AB (Liat) in nasal samples. Methods: Nasal and nasopharyngeal samples were collected and were tested using the Liat, the cobas 6800 system and the cobas SARS-CoV-2 & Influenza AB (cobas), and a method developed by National Institute of Infectious Diseases, Japan (NIID). Results: A total of 814 nasal samples were collected. The Liat assay was positive for SARS-CoV-2 in 113 (13.9%). The total, positive, and negative concordance rate between the Liat and cobas/NIID assays were 99.3%/98.4%, 99.1%/100%, and 99.3%/98.2%, respectively. Five samples were positive only using the Liat assay. Their Ct values ranged from 31.9 to 37.2. The Ct values of the Liat assay were significantly lower (p < 0.001) but were correlated (p < 0.001) with those of other molecular assays. In the participants who tested positive for SARS-CoV-2 on the Liat assay using nasopharyngeal samples, 88.2% of their nasal samples also tested positive using the Liat assay. Conclusion: The Liat assay showed high concordance with other molecular assays in nasal samples. Some discordance occurred in samples with Ct values > 30 on the Liat assay.

The pandemic of severe acute coronavirus 2 (SARS-CoV-2) has had a detrimental effect on society globally [1] . The introduction of effective vaccines [2] and treatment [3] were expected to effectively control the pandemic; however, the numbers of new infections and deaths have increased in some countries [1] . Currently, population-based screening and early detection and isolation of infected individuals are still key to effective infection control [4] .

The standard method for detecting SARS-CoV-2 is molecular testing due to its high diagnostic performance [5] . However, molecular diagnostics are less widely available and less convenient than antigen testing, and the turnaround time is longer [6] .

Several molecular point-of-care tests (POCTs) have been developed [7] and applied in clinical settings to overcome the disadvantages of traditional molecular tests. The cobas Liat system (Roche Molecular Systems, Inc., Pleasanton, CA, USA) is a small analyzer that automatically performs real-time polymerase chain reaction (PCR) testing using simple procedures and provides results within 20 minutes [8] . The system has been used for point-of-care testing, and Liat assays are available for influenza virus [9] , respiratory syncytial virus [10] , Clostridioides difficile [11] , group A Streptococcus [12] , and SARS-CoV-2 [8] . The Liat system and cobas Liat SARS-CoV-2 & Influenza AB (Liat) has been shown to have high sensitivity for detecting SARS-CoV-2 in nasopharyngeal samples [8] , but the diagnostic performance with nasal samples has not been reported. Nasal sample collection is easier and less invasive than the nasopharyngeal sample collection [13] ; therefore, the clinical utility of Liat would be greater if it could accurately detect SARS-CoV-2 in nasal samples.

In this study, we prospectively evaluated the diagnostic performance of the Liat . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.07.22268874 doi: medRxiv preprint SARS-CoV-2 assay using paired samples collected from the anterior nostrils and the nasopharynx of participants. The Liat results of the anterior nasal samples were compared with the results of two other real-time PCR tests.

This study was conducted in a PCR center located in Tsukuba Medical Center Hospital (TMCH) in Japan between July 7 and 29, 2021. The participants were outpatients who were suspected to have SARS-CoV-2 infection due to their symptoms or the history of close contact who underwent in-house PCR testing at the center [14] .

They included individuals referred from 51 healthcare facilities and a local healthcare center, and healthcare workers working at TMCH. Clinical information of the participants was routinely recorded along with the in-house PCR. Verbal informed consent was obtained from all participants, and the ethical board of the University of Tsukuba approved the study (approval number: R03-41).

One nasopharyngeal and two nasal samples were collected from each participant. The nasopharyngeal samples were collected as described previously [15] .

Nasal samples were collected from the anterior nostrils according to recommended procedures [16] . Briefly, the swab was inserted to a depth of approximately 2 cm and rotated four times against the nasal mucosa. The procedure was repeated in the other nostril using the same swab. One nasal swab sample was used for molecular testing using Liat, and the other nasal swab sample was used for the evaluation of antigen testing in another study. All nasal sample collections for molecular testing followed . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.07.22268874 doi: medRxiv preprint those for antigen testing.

Both the nasal and nasopharyngeal swab samples were diluted in Universal Transport Medium (UTM TM ; Copan Diagnostics Inc., Murrieta, CA, USA) and stored at −80°C. The nasopharyngeal samples were frozen after being testing using an in-house PCR test.

After being thawed, all nasal samples underwent PCR testing according to three methods: i) cobas Liat system and cobas Liat SARS-CoV-2 & Influenza AB (Liat), ii) cobas 6800 system and cobas SARS-CoV-2 & Influenza AB (cobas; Roche Molecular Systems, Branchburg, NJ, USA) [17] , and iii) a national standard method developed by National Institute of Infectious Diseases (NIID), Japan [18] . If a sample showed positivity on one of the methods and negativity on the other two, they were tested using the Gene Xpert system and the Xpert Xpress SARS-CoV-2 (Xpert Xpress; Cepheid, Sunnyvale, CA, United States) [19] .

The nasopharyngeal samples were tested using Liat and the NIID test for the evaluation and were not tested using the cobas system due to an insufficient amount of residual UTM sample. If the Liat and NIID results were discordant, the samples were tested using Xpert Xpress, in a similar manner to the nasal samples.

Liat, cobas, and Xpert Xpress perform sample preparation (purification and the extraction of RNA), real-time PCR, and the detect of the viruses using a fully automated process. For the Liat assay, a total of 200μL of UTM TM sample was loaded into the test cartridge, which was then inserted into the system. The Liat test targets the ORF1a/b and N gene and shows positive results if one or both genes are detected. We re-tested . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 10, 2022. The Ct values were automatically calculated after the detection of SARS-CoV-2 for all test methods used in this study.

Apart from detecting SARS-CoV-2, the Liat assay can also detect influenza virus; however, the results have not been re-evaluated and validated by confirmatory molecular assays in this study.

The results of the Liat assay were compared with those of the other molecular . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.07.22268874 doi: medRxiv preprint assays, and the concordance was calculated with 95% confident intervals (CIs), using the Clopper and Pearson method. The Wilcoxon signed-rank test was used to compare the median Ct values. The correlations of the Ct values between two molecular assays were assessed using Pearson's product-moment correlation coefficient. The statistical analyses were performed using R version 3.14.1 (R Foundation for Statistical Computing, Vienna, Austria), and the figures were created using Python version 3.8.12

(Python Software Foundation, Wilmington, DE, USA).

The study included a total of 843 participants, of whom 29 provided only nasopharyngeal samples. Therefore, we obtained 814 nasal and 843 nasopharyngeal samples. The Liat assay could not be performed on one nasopharyngeal sample due to the insufficient amount of residual sample (case ID: T0725). 

The results of the Liat assay are compared with the results of the cobas and NIID assays performed using nasal samples in Tables 1 and 2, respectively. The total, positive, and negative concordance between the Liat and cobas assays were 99.3%, 99.1%, and 99.3%, respectively. The comparison was also performed stratified by the presence of relevant symptoms. In the symptomatic participants, the total, positive, and negative concordance was 99.4%, 100%, and 99.3%, respectively. In the asymptomatic participants, the total, positive, and negative concordance was 99.2%, 97.9%, and 99.3%, respectively. Table 2 ). Eight of the 13 samples were positive on cobas assay. There were six sets of discordant results between the cobas and Liat assays, of which one sample was Liat-negative/cobas-positive and five samples were Liat positive/cobas negative.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 1

The correlation of the Ct values of the Liat assay and the other assays is shown in Figure 1 (a, b, c) . The median Ct values for each assay were as follows: Liat, 16.70; NIID, 23.7; cobas ORF1a/b gene, 24.4; cobas E gene, 23.6. The Ct values of the Liat assay were significantly lower (p < 0.001) but were correlated (p < 0.001) with those of the other assays. Figure 2 (a, b) . Table 3 summarizes the results of the discordant cases: nasal samples with positive results on only one of the three molecular assays (left panel) and

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.07.22268874 doi: medRxiv preprint nasopharyngeal samples with discordant results of the Liat and NIID assay (right panel).

Additional analyses using Xpert Xpress were performed for these cases, although one sample (case ID: T0198) could not be tested due to the lack of residual sample volume.

In nasal samples, five samples were positive only using the Liat assay (Ct value range: 31.9-37.2), and one sample was positive only using the cobas assay (Ct value: 

This prospective evaluation showed the high concordance in the nasal samples of the Liat assay results with those of other molecular assays. The Ct values of the Liat assay were significantly lower than those of other molecular assays, but were significantly correlated, although some discordant results were observed. Most of the cases of discordance occurred in samples with Ct values >30 on the Liat assay.

In nasopharyngeal samples, the total, positive and negative agreement of the results of the Liat and the cobas 6800/8800 assays were 98.6%, 100%, and 97.4%, respectively [8] . Similarly, this study showed high concordance between the results of the Liat assay and other molecular assays in nasal samples. The Liat assay can provide accurate results in 20 minutes and the equipment is compact. This enable the Liat system to be applied in a variety of settings, such as for rapid diagnosis in primary care . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. The Ct values of the Liat assay were strongly correlated with those of the cobas and NIID assays, but were significantly lower. Determining the Ct values is crucial to identify which patients with SARS-CoV-2 infection are most likely to transmit the virus, with higher Ct values indicating lower infectivity [23, 24] . However, Ct values can vary depending on the reagents and equipment used, even if the same samples are tested [24] ; thus, the Ct values provided by each set of equipment should be carefully interpreted.

The study also compared the results of the tests of the nasal samples with those of the nasopharyngeal samples collected from the same participants. Some discordance occurred between nasal and nasopharyngeal RT-PCR results, with the nasal samples being more likely to provide negative results. A meta-analysis found that the sensitivity of RT-PCR of nasal samples was 82% compared to RT-PCR of nasopharyngeal samples . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 4 [25] . In this study, 88.2% of nasal samples tested positive using the Liat assay among participants whose nasopharyngeal samples tested positive using the Liat assay. The Ct values between both sample types were strongly correlated but varied. The viral load is generally lower in the nostrils than in the nasopharynx [25] , although the procedures for sample collection and the conditions of samples may also have caused the fluctuation of their Ct values [24] .

In the coming winter season, the influenza virus is likely to co-circulate with SARS-CoV-2 infection [26, 27] . Many clinical manifestations of influenza virus infection are similar to those of SARS-CoV-2 infection [28] , which makes the clinical diagnosis difficult. Nevertheless, the distinction of the two viruses may affect the initial choice of treatment and infection control measure. The Liat system is reported to accurately identify the influenza virus [9] , although due to the limited scope of the present study we did not verify the results by using other molecular assays. We consider that the system can make significant contributions to daily clinical practices because of its feature of detecting both viruses simultaneously.

Our study has some limitations. First, we were unable to perform cobas testing on nasopharyngeal samples. The cobas assay has a high sensitivity and has been widely used worldwide [29, 30] . The level of discordance may vary depending on the equipment used for comparison. Second, we did not evaluate performance of the assays in samples from individuals infected with SARS-CoV-2 variants with gene mutations.

The emergence of new variants could affect the diagnostic performance of the test.

Third, the nasal samples used for molecular examination were collected after acquiring those used for antigen testing. The viral load in the nasal samples may have reduced due to the order of the procedure, which may have led to the variations in results obtained in . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.07.22268874 doi: medRxiv preprint the molecular examination. Finally, we did not use fresh samples for the evaluation of molecular examinations. Although to a miniscule degree, the storage process involving freezing and thawing also reportedly affects the viral load in samples [31] .

In conclusion, the results of the Liat assay showed a high concordance with those of the other molecular assays in both nasal and nasopharyngeal samples. The findings of our study suggests that the Liat assay is suitable for use in a variety of clinical situations, primarily where accurate detection of SARS-CoV-2 is necessary. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 6

This study was financially supported by Roche Diagnostics K.K.

Roche Diagnostics K.K., provided support in the form of salaries to author Michiko Horie, Kenichi Togashi, and Yuki Adachi. Molecular examinations using Liat, cobas, NIID, and Xpert Xpress were performed with financial support from Roche Diagnostics K.K. Hiromichi Suzuki was awarded lecture fee from Roche Diagnostics K.K.

The study was performed in accordance with the principles of the Declaration of Helsinki and with the STROBE guidelines and was approved by the ethics committee of the University of Tsukuba (approval number: R03-41).

Verbal informed consent was obtained from all participants.

Not applicable.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.07.22268874 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. The 95% confidence intervals are given in parentheses. The 95% confidence intervals are given in parentheses.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.07.22268874 doi: medRxiv preprint

World Health Organization. Coronavirus disease (COVID-19) Weekly

Epidemiological Update and Weekly Operational Update

Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized

COVID-19) Treatment Guidelines

COVID-19 Treatment Guidelines

Testing at scale during the COVID-19 pandemic

World Health Organization. Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities

Infectious Diseases Society of America

In Vitro Diagnostics EUAs -Molecular Diagnostic Tests for SARS-CoV-2

Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV

Minutes: a Multicenter Study

Analytical and clinical evaluation of a point-of-care molecular diagnostic system and its influenza A/B assay for rapid molecular detection of the influenza virus

In-house validation of the cobas Liat influenza A/B and RSV assay for use with gargles, sputa and endotracheal secretions

Evaluation of the Liat Cdiff Assay for Direct Detection of Clostridioides difficile Toxin Genes within 20 Minutes

Accurate Detection of Streptococcus pyogenes at the Point of Care Using the cobas Liat Strep A Nucleic Acid Test

Diagnostic performance and characteristics of anterior nasal collection for the SARS-CoV-2 antigen test: a prospective study

A Prospective Evaluation of the Analytical Performance of GENECUBE ® HQ SARS-CoV-2 and GENECUBE ® FLU A/B

Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing

Comparison of Two High-Throughput Reverse Transcription-PCR Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2

Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus

Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test

Comparative performance and cycle threshold values of 10 nucleic acid amplification tests for SARS-CoV-2 on clinical samples

Molecular diagnostic technologies for COVID-19: Limitations and challenges

Viral cultures for COVID-19 infectious potential assessment -a systematic review

Viral Dynamics and Real-Time RT-PCR Ct Values Correlation with Disease Severity in COVID-19

Performance of Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: A Systematic Review and Meta-analysis

Winter pressure: RSV, flu, and covid-19 could push NHS to breaking point, report warns

Winter is coming-but will the gloomiest forecasts come to pass?

Comparison of Clinical Characteristics for Distinguishing COVID-19 From Influenza During the Early Stages

Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic

Roche's cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark

Prolonged Unfrozen Storage and Repeated Freeze-Thawing of SARS-CoV-2 Patient Samples Have Minor Effects on SARS-CoV-2 Detectability by RT-PCR

author/funder, who has granted medRxiv a license to display the preprint in perpetuity